CXL Coming to a TLC Near You

posted Oct 31, 2016, 11:06 AM by Jen Weigel
October 28, 2016
 
Dear Doctor,
 
We are excited to announce that TLC Tysons Corner will begin offering the corneal cross-linking procedure very soon.  As you may already know, the FDA recently approved corneal cross-linking using KXL light system and Photrexa Viscous/Phorexa riboflavin formulas. This specific treatment combination is currently the only FDA-approved therapeutic modality for patients with progressive keratoconus.  For the first time, we now have an effective treatment clinically proven to prevent or slow down progression for our keratoconus patients.
 
How it Works
 
The procedure is simple for patients: Riboflavin eye drops are applied to the cornea for 30 minutes after epithelial removal, followed by exposure of the cornea to KXL light system for another 30 minutes. The procedure works by creating new corneal “cross-links”, which results in stiffening and strengthening of stromal tissue.
 
Benefits to Your Patients
 
•             The only FDA-approved, non-surgical keratoconus treatment available
•             The only treatment proven to halt or slow down the progression of disease
•             The only treatment shown to clinically stiffen corneal tissue
•             The only FDA-approved procedure that provides a true long-term solution for your patients
 
Who is Eligible?
 
Corneal cross-linking can be indicated for any patient who has been diagnosed with progressive keratoconus and who is 14 years of age or older.
 
Your patients’ vision and quality-of-life are very important to TLC and that is why we will be adding corneal cross-linking as a new service offering.  These patients often require ongoing care and advanced contact lens fittings as their cornea remodels over time.  As always, your expertise is an integral part of our co-management relationship. This is essential to ensure that treatment success is achieved for each patient in the long run. We will be happy to discuss how best to manage these cases with you.
 
Should you have any questions about corneal cross-linking, please do not hesitate to contact us. As always, we thank you for your continued support and trusting TLC with your patients.
 
Sincerely,
 
Your TLC Tysons Team
 
Andrew Holzman, MD, FACS, Regional Medical Director      
Jen Weigel, OD, FAAO, Clinical Director
Natasha Carter, Center Manager       
Joan Reich, Professional Relations Consultant
Comments